This conference call transcript was computer generated and almost certianly contains errors. This transcript is provided for information purposes only.EarningsCall, LLC makes no representation about the accuracy of the aforementioned transcript, and you are cautioned not to place undue reliance on the information provided by the transcript.

Evotec SE
11/5/2026
Ladies and gentlemen, welcome to the Evotec SE third quarter and nine months 2026 results conference call. I am Sandra, the course co-operator. I would like to remind you that all participants have been listened only more than the conference is being recorded. The presentation will be followed by a Q&A session. You can register for questions at any time by pressing star and one on your telephone. For operator assistance, please press star and zero. The conference must not be recorded for publication or broadcast. At this time, it is my pleasure to hand over to Sarah Fakih, Head of Corporate Communication and IR. Please go ahead. Thank you, Sandra.
Good morning, good afternoon and welcome to today's webcast and conference call. My name is Sarah Fakih and I'm the Head of Corporate Communications and Investor Relations at Evotec. Please allow me to introduce today's speakers. Joining me on the call are Christian Wojczewski, Chief Executive Officer of Evotec, and Claire Hinshelwood, our Chief Financial Officer. Please note that this call is being webcast live and will be archived in the event calendar on our website. Before we begin, a few forward-looking statements. The discussion and responses to your questions on this call reflect management's view as of today, Thursday, November 5th, 2026. During this call, we will make statements and provide responses that state our intentions, beliefs, expectations or projections regarding the future. These statements constitute forward-looking statements within the meaning of applicable securities laws. They are subject to risks and uncertainties and actual results may differ materially from those expressed or implied. Evotec disclaims any intention or obligation to update or revise any forward-looking statements to reflect subsequent events or circumstances. For further information regarding these risks and uncertainties, please refer to our public filings and disclosures. With this, let me hand over the call to Christiane.
Thank you, Sarah. Good morning and good afternoon to everyone. Thank you for joining today's call. The third quarter of 2026 showed encouraging progress after a challenging first half. We're beginning to see the different pieces of our transformation come together. and translate into improved business performance. Group revenues in Q3 were above both Q1 and Q2, mainly driven by stronger commercial execution in the DMPD-based business. At the same time, lower costs brought adjusted group EODA close to breakeven. The nine-month results still reflect the weaker first half, including slower sales-to-revenue conversion in DMPD and the Sandoz license contribution in JEP in the first quarter of 2025. Our commercial ramp up in DMPD is gaining traction. Net sales in the base business were up 24% for the first nine months year over year. In this shorter cycle of business, we're now beginning to see stronger commercial activity convert into revenue growth. In just Evotec Biologics, we're excited to confirm that Vertex Pharmaceuticals has selected us for the commercial manufacturing of ProV-TaseSept at our GPOD Redmond facility. This is an important step for JEP as we advance our continuous manufacturing platform toward commercial scale readiness. Alongside this progress, Horizon Execution is well on track. Our target is to deliver approximately 75 million euros in annual run rate savings by the end of 2027. For this year, we plan to deliver 20 to 30% of this target. By the end of September, we had already delivered more than 20% of the target, putting us ahead of plan. Footprint consolidation and workforce measures are starting to deliver tangible savings. while our focus on utilization and operational efficiency is supporting improved profitability. These developments give us greater confidence in the direction of the business. We reaffirm our full year 2026 guidance and based on our current visibility, expect revenue and adjusted ABDA to land toward the upper end of their respective ranges. Later in the call, we will provide greater detail on our mid-range framework through 2030. This will give you better visibility into the business and a clearer view of the path forward, including how we expect the business mix to evolve and support a structurally stronger earnings profile. But before we move into the detailed review of the third quarter and first nine months, I'd like to highlight an important transition in our scientific leadership. Science is at the core of Evotech, and I'm therefore very pleased to introduce Dr. Joanna Holbrook. Joanna joined Evotech as chief scientific officer and member of the management board on November 1st. She succeeded Cord Dohrmann, who left Evotech at the end of September. I'd like to take the opportunity to thank Cord for his many contributions over more than 16 years. He played an important role in building the scientific capabilities and innovation culture Evotech is known for. We're excited to have attracted a scientific leader of Joanna's caliber to Evotech. Joanna brings more than 25 years of international experience across pharma, biotech, and academia. Most recently, she held senior scientific leadership roles at Novo Nordisk, Previously, she served as Chief Scientific Officer at Biomodel. Joanna combines deep scientific expertise with a strong track record in applying new technologies and data-driven approaches to drug discovery and development. Her experience across different scientific environments, organizational structures, and cultures adds a broad perspective that will be particularly valuable as we continue to evolve evotec. As chief scientific officer, Joanna's focus will be clear. To strengthen our scientific profile and translate advances in data science, AI, and novel technologies into greater value for customers and partners. On slide six, let me continue with an overview of recent progress across selected partnerships. The most important development is in Just Iverdeck Biologics, where we confirm that Vertex Pharmaceuticals has selected JEP for the commercial manufacturing of povitacicept, Vertex Investigational Biologic Candidate for a Serious Kidney Disease. Alongside this exciting progress, we're adding a third manufacturing train at our J-Port Redmond facility next year. expanding manufacturing capacity for the next phase of JEP's growth. The additional capacity also positions us well to meet our manufacturing and supply commitments to Vertex. Furthermore, in our collaboration with the Department of War, JEP advanced the Orto-Pox virus antibody program into a phase one clinical trial, having progressed the program from sequence to clinical supply. In DMPD, we continue to broaden our partnered innovation activities. The first candidate from our sleep disorder discovery collaboration with Jazz Pharmaceuticals has advanced into phase one clinical trial. Further, new and recent collaborations span next-generation therapeutic oncology approaches with Plektronik and AI-enabled drug discovery with Odyssey Therapeutics. Let me now hand the call over to Claire for review of the Q3 and first nine-month 2026 financials.
You're reading a preview of the EVO Q3 2026 earnings call.
Free account.
Want transcripts like this in your own app? Try the Earnings call API, or read the transcript API docs.
Use this data in your own app
Pull this call's transcript, audio and slides with the Earnings call transcripts API.
See pricing